Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Northern Trust Corp

Northern Trust Corp increased its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 16.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 24,658,360 shares of the biopharmaceutical company's stock after buying an additional 3,431,248 shares during the period. Northern Trust Corp owned about 1.22% of Bristol-Myers Squibb worth $1,394,677,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Shorepoint Capital Partners LLC raised its stake in Bristol-Myers Squibb by 2.2% during the 4th quarter. Shorepoint Capital Partners LLC now owns 58,426 shares of the biopharmaceutical company's stock valued at $3,305,000 after purchasing an additional 1,248 shares during the period. Tri Locum Partners LP bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $20,100,000. Berger Financial Group Inc lifted its holdings in shares of Bristol-Myers Squibb by 1.5% in the fourth quarter. Berger Financial Group Inc now owns 104,022 shares of the biopharmaceutical company's stock worth $5,884,000 after buying an additional 1,498 shares in the last quarter. Johnson Financial Group Inc. boosted its position in shares of Bristol-Myers Squibb by 246.8% during the fourth quarter. Johnson Financial Group Inc. now owns 15,866 shares of the biopharmaceutical company's stock worth $946,000 after acquiring an additional 11,291 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $1,495,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction on Friday, April 25th. The shares were acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. The trade was a 5.36 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research reports. UBS Group decreased their price objective on Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Truist Financial increased their price objective on shares of Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Piper Sandler started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 target price on the stock. Argus raised shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Wells Fargo & Company boosted their price objective on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of "Hold" and a consensus target price of $58.00.

Bristol-Myers Squibb Trading Down 1.3 %

Shares of NYSE:BMY traded down $0.67 during trading on Thursday, reaching $49.53. 17,161,789 shares of the company were exchanged, compared to its average volume of 12,973,691. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The firm has a market capitalization of $100.79 billion, a PE ratio of -11.21, a P/E/G ratio of 2.07 and a beta of 0.41. The business's fifty day simple moving average is $55.99 and its 200-day simple moving average is $56.41. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. The business's revenue for the quarter was down 5.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($4.40) EPS. On average, research analysts anticipate that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 annualized dividend and a dividend yield of 5.01%. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.